# A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct06234423/  
OnCo record `nct06234423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CUSP06 run by OnCusp Therapeutics, Inc., now recruiting.

## Summary

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors is a phase 1 interventional study registered as NCT06234423 by OnCusp Therapeutics, Inc., with 263 participants planned, started 2024-02-09. Conditions recorded: Ovarian Cancer and Solid Tumor. Interventions recorded: CUSP06.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06234423
- Phase: 1
- Setting: A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Sponsor: OnCusp Therapeutics, Inc.
- Enrolled: 263

## Sources

- ClinicalTrials.gov NCT06234423: https://clinicaltrials.gov/study/NCT06234423

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [CUSP06](https://onco.cc/drugs/amt-707/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/), [OnCusp Therapeutics](https://onco.cc/companies/oncusp-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06234423.json